PKM and colorectal carcinoma: This present study deepens our understanding of molecular mechanisms underlying chemotherapy resistance of oxaliplatin in CRC cells by proposing that knockdown of PKM2/GLS1 expression may constitute a novel therapeutic strategy toward effective treatment for CRC in clinical practice.